Balance Sheet
Includes Current Assets, Liabilities and Stockholder's Equity
Latest Financial Results
Q1 2024
Quarter Ended Mar 31, 2024
$5.7M
Revenue for the three months ended March 31, 2024, was $5.7 million compared to $47.6 million for the same period in 2023
$140.7M
As of March 31, 2024, Adaptimmune had cash and cash equivalents of $140.7 million and Total Liquidity1 of $143.7 million, compared to $144.0 million and $146.9 million respectively, as of December 31, 2023
1Total liquidity is a non-GAAP financial measure, which is explained and reconciled to the most directly comparable financial measures prepared in accordance with GAAP below.
Latest Annual Filing
For Fiscal Year Ending Dec 31, 2023
Report Links
For complete information regarding our financials, see our periodic filings